Employees and Remuneration Section: Forecasting Human Capital Cost Trends

The Employees and Remuneration section of a prospectus has long been treated by issuers and their sponsors as a compliance-driven disclosure — a mechanical recitation of headcount, cost ratios, and option scheme rules. That assumption is breaking down in the 2025-2026 listing cycle. The Hong Kong Stock Exchange (HKEX) has intensified its focus on workforce-related disclosures, particularly for issuers in labour-intensive sectors such as healthcare, retail, and technology services. In December 2024, the HKEX published its Guidance Letter GL117-24, which explicitly flagged remuneration policies, employee turnover rates, and reliance on contract labour as material risk factors requiring granular prospectus disclosure under Listing Rules Chapter 11 (for Main Board) and Chapter 7 (for GEM). Simultaneously, the Hong Kong Monetary Authority (HKMA) has been tightening its scrutiny of deferred compensation structures for listed financial institutions under its Supervisory Policy Manual CA-G-5 (revised March 2025), creating a direct regulatory overlay between prospectus disclosures and post-listing prudential compliance. For issuers preparing to file an A1 application in Hong Kong or a Form F-1 with the SEC, the Employees and Remuneration section is no longer a boilerplate appendix — it is a forward-looking financial statement in its own right, one that analysts and institutional investors are using to model future cash flows, margin trajectories, and retention risk. The cost of human capital now accounts for between 35% and 65% of total operating expenses for most Main Board applicants (HKEX 2024 IPO Statistics Report), making the accuracy and depth of this disclosure a direct input into valuation multiples.

The Structural Anatomy of the Employees and Remuneration Section

Headcount Disclosure: From Static Count to Dynamic Flow

The traditional prospectus approach to headcount disclosure — a single table showing total employees by function at the latest practicable date — is no longer sufficient under current HKEX review practices. The Exchange’s Listing Division now routinely requests a three-year historical breakdown of headcount by employment type (permanent, contract, part-time), by geographic region (Hong Kong, PRC, and other jurisdictions), and by cost centre (R&D, sales, administration, production). This requirement is codified in the HKEX Guide for New Listing Applicants (2024 edition), Section 8.3.2, which states that “an issuer should disclose the number of its employees, including the number of employees in each major category of its business, and the number of its employees who are also directors.”

For issuers with a significant presence in the People’s Republic of China (PRC), the disclosure must also address the legal distinction between direct employees and those engaged through labour dispatch agencies — a distinction governed by the PRC Labour Contract Law (Article 58-66). The HKEX has, in recent review comments, required applicants to quantify the proportion of workers engaged through third-party human resources service providers, and to disclose whether those arrangements comply with the statutory cap of 10% of total workforce for dispatch workers (PRC Labour Dispatch Interim Provisions, Article 4). Failure to do so has resulted in at least three A1 return letters in the first quarter of 2025 (source: Hong Kong IPO Watch, Q1 2025 review).

Remuneration Structure: Base, Variable, and the Deferred Component

The remuneration disclosure must disaggregate total employee compensation into at least three components: fixed base salary, variable cash bonuses, and equity-based incentives (stock options, restricted share units, or share appreciation rights). For Main Board applicants, the HKEX Listing Rules require a five-year summary of total staff costs under Rule 4.09(2), presented as a separate line item in the accountants’ report. However, the more operationally relevant disclosure appears in the “Management Discussion and Analysis” (MD&A) section, where the issuer must explain the relationship between remuneration changes and business performance.

A specific area of regulatory focus in 2025 is the treatment of deferred compensation for senior management and key personnel. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Chapter 571, subsidiary legislation) was amended in November 2024 to require that “at least 40% of variable remuneration for senior management of listed entities shall be deferred for a minimum period of three years, with clawback provisions triggered by material financial restatements or compliance failures” (SFC Code of Conduct, Paragraph 17.6A). This requirement directly impacts the prospectus disclosure of post-IPO remuneration policies, as issuers must now describe their deferred compensation framework in the “Employees” section of the prospectus, not merely in the corporate governance report.

Forecasting Human Capital Cost Trends: The Forward-Looking Dimension

The Implicit Cost of Employee Turnover

The single most under-disclosed item in prospectus Employees sections is the cost of employee turnover. While most issuers provide a voluntary turnover rate — typically expressed as a percentage of total headcount per annum — very few quantify the direct financial impact of replacement costs, training expenditure, and productivity loss. The HKEX’s Guidance Letter GL117-24 specifically advises that “where an issuer has experienced or expects to experience a material change in its employee turnover rate, it should disclose the estimated financial impact on its cost of sales and operating expenses.”

For a technology or healthcare issuer, the replacement cost of a single senior R&D engineer in Hong Kong or Shenzhen can range from HKD 800,000 to HKD 1.5 million, inclusive of recruitment agency fees, signing bonuses, and onboarding training (source: Hays Hong Kong Salary & Recruiting Trends 2025 Report). When annual turnover exceeds 25%, the cumulative cost can reduce EBITDA margins by 200-400 basis points — a materiality threshold that any prospectus MD&A should address. Institutional investors in the 2025 IPO pipeline have begun requesting this data in their due diligence questionnaires, and several family offices have indicated they will discount valuation multiples by 0.5x-1.0x for issuers that fail to provide a quantified turnover cost analysis.

Minimum Wage, Social Insurance, and PRC Labour Cost Convergence

For issuers with material operations in the PRC, the Employees and Remuneration section must reflect the rapidly converging labour cost environment across Chinese cities. The PRC Ministry of Human Resources and Social Security raised the national minimum wage floor by an average of 8.2% in 2024 (MOHRSS Circular No. 2024-15), with tier-1 cities such as Shanghai and Beijing implementing increases of 10.5% and 9.8% respectively. These increases directly affect the base salary component of the prospectus remuneration table, and the HKEX has required applicants to disclose the sensitivity of their total staff costs to a 1% change in minimum wage across each jurisdiction of operation.

The social insurance burden in the PRC — comprising pension insurance (16% employer contribution), medical insurance (8.5%), unemployment insurance (0.5%), work-related injury insurance (0.2%-1.9%), and maternity insurance (1%) — now totals approximately 26.2% to 27.4% of gross salary for employers in most provinces (PRC Social Insurance Law, Article 12-23). This is a fixed cost that cannot be avoided through restructuring, and it has a direct impact on the effective cost per employee disclosed in the prospectus. For issuers that historically under-reported social insurance contributions — a practice that the State Administration of Taxation has been auditing aggressively since 2023 — the prospectus must disclose any historical non-compliance and the estimated financial impact of remediation.

The Equity Compensation Line Item: Vesting Schedules and Dilution Impact

The equity compensation portion of the Employees section is where the most complex financial modelling occurs. Under HKEX Listing Rules Chapter 17 (Share Schemes), issuers must disclose the total number of shares that may be issued under all share schemes, the vesting period for each tranche, and the performance conditions attached to each grant. The prospectus must also include a pro-forma dilution table showing the impact of full exercise of all outstanding options and awards on earnings per share (EPS) for the most recent three financial years.

A critical forward-looking metric that is often omitted is the “run rate” of equity compensation — the annualised cost of share-based payments as a percentage of revenue. For technology issuers in the 2025 pipeline, this run rate has ranged from 3% to 12% of revenue (source: Dealogic Hong Kong IPO Database, Q1 2025). When combined with the cash cost of social insurance and minimum wage increases, the total human capital cost can represent 50-70% of revenue for early-stage growth companies. The prospectus must therefore include a sensitivity analysis showing the impact of a 10% increase in equity compensation cost on net profit — a disclosure that is now standard practice in SEC S-1 filings but remains inconsistently applied in Hong Kong prospectuses.

Sector-Specific Human Capital Cost Drivers

Healthcare and Biotech: The Clinical Trial Labour Premium

For healthcare issuers listing under HKEX Chapter 18A (Biotech) or Chapter 18C (Specialist Technology), the Employees and Remuneration section must address the specialised nature of clinical trial personnel. The cost of a clinical research associate (CRA) in Hong Kong or the Greater Bay Area has risen by 18-22% year-on-year since 2023, driven by a shortage of qualified professionals with Good Clinical Practice (GCP) certification (source: Hong Kong Medical and Healthcare Device Industries Association, 2025 Salary Survey). The prospectus should disclose not only the headcount of clinical staff but also the average cost per clinical trial phase, as this directly affects the burn rate disclosed in the “Use of Proceeds” section.

The HKEX’s Guidance Letter GL92-18 (updated January 2025) requires biotech issuers to disclose the key personnel responsible for clinical development and regulatory affairs, including their employment terms, non-compete clauses, and the estimated cost of replacing each individual. This is a material disclosure because the departure of a single principal investigator or regulatory affairs director can delay a clinical trial by 6-12 months, with a direct cost impact of HKD 20-50 million per delay event.

Retail and Consumer: The Minimum Wage and Hourly Labour Cost Trap

Retail issuers listing on the Main Board face a unique human capital cost challenge: the interaction between minimum wage laws, overtime regulations, and the use of part-time workers. In Hong Kong, the Statutory Minimum Wage rate was raised to HKD 42.5 per hour effective 1 May 2025 (HK Labour Department Gazette, March 2025). For a retail chain with 500 employees, each HKD 1 increase in the minimum wage adds approximately HKD 1.04 million to annual staff costs (assuming 2,080 working hours per full-time equivalent). The prospectus must disclose this sensitivity explicitly, as it is a direct input into the issuer’s margin forecast.

In the PRC, the Labour Contract Law (Article 39) and the Regulations on the Implementation of the Labour Contract Law (Article 18) impose strict limits on overtime hours — a maximum of 36 hours per month. Retail issuers that rely on extended store hours must disclose their overtime cost as a separate line item, and the HKEX has required several 2025 retail applicants to include a legal opinion from PRC counsel confirming compliance with overtime regulations. Non-compliance can result in administrative penalties of up to RMB 20,000 per employee per violation (PRC Labour Inspection Regulations, Article 15), a contingent liability that must be quantified in the prospectus risk factors.

Technology and SaaS: The Equity Compensation Runway

For technology issuers, particularly those with a Software-as-a-Service (SaaS) revenue model, the equity compensation line item is the single largest human capital cost driver. The median equity compensation run rate for Hong Kong-listed technology companies in 2024 was 8.7% of revenue (source: HKEX Annual Review of Share Schemes, 2024). For pre-profit issuers, this cost is often the primary reason for negative net profit, and the prospectus must clearly distinguish between cash-based employee costs and non-cash share-based payment expenses.

The HKEX’s Listing Decision LD127-2024 clarified that share-based payment expenses must be recognised in the income statement from the date of grant, using the fair value method under HKFRS 2. This means that the prospectus’s pro-forma financial statements must include a full valuation of each option grant, using a Black-Scholes or binomial model, and must disclose the key assumptions — expected volatility, risk-free rate, expected life, and dividend yield. Institutional investors in the 2025 IPO market have begun comparing these assumptions across peer issuers, and any deviation from industry norms (e.g., an expected volatility assumption below 35% for a tech issuer) will trigger detailed due diligence questions.

The Regulatory Horizon: What the 2025-2026 Listing Cycle Demands

The HKEX’s Enhanced Scrutiny of Remuneration Committees

The HKEX’s Corporate Governance Code (Appendix 14 to the Main Board Listing Rules) was revised effective 1 January 2025 to require that the remuneration committee of every listed issuer must include at least one independent non-executive director (INED) with expertise in human capital management or compensation design (Code Provision E.1.2). This requirement applies to all new listing applicants from the date of listing, and the prospectus must disclose the biographical details of the INED who will serve on the remuneration committee, including their relevant experience.

This regulatory change has a direct impact on the prospectus drafting process. Issuers must now include a section describing the post-listing remuneration committee’s terms of reference, including its authority to approve equity grants, set performance targets, and enforce clawback provisions. The prospectus should also disclose the committee’s planned meeting frequency and the criteria it will use to evaluate the CEO’s performance — a level of detail that was previously reserved for the annual report.

The SEC’s Pay Versus Performance Disclosure: Cross-Border Implications

For issuers pursuing a dual listing in Hong Kong and the United States, the SEC’s Pay Versus Performance disclosure rule (Item 402(v) of Regulation S-K) requires a tabular comparison of executive compensation actually paid versus total shareholder return (TSR) over a five-year period. While this rule applies to SEC registrants, HKEX-listed issuers that also file Form 20-F are increasingly adopting a similar disclosure in their Hong Kong prospectuses to avoid inconsistency between the two regulatory regimes.

The practical implication for the Employees and Remuneration section is that issuers must now calculate “compensation actually paid” — a metric that includes the change in fair value of equity awards during the fiscal year, rather than the grant-date fair value used in the summary compensation table. This calculation requires a separate set of assumptions and a reconciliation to the financial statements, adding significant complexity to the prospectus disclosure. At least three 2025 dual-listing applicants have included a “Pay Versus Performance” table in their Hong Kong prospectus as a voluntary disclosure, citing investor demand for alignment between executive pay and long-term shareholder value creation.

The HKMA’s Deferred Compensation Requirements for Financial Institutions

For financial institutions listing on the Main Board, the HKMA’s Supervisory Policy Manual CA-G-5 (revised March 2025) imposes a mandatory deferred compensation structure for “material risk takers” — defined as employees whose total remuneration exceeds HKD 3 million per annum and whose activities have a material impact on the institution’s risk profile. The manual requires that at least 60% of variable remuneration for material risk takers be deferred for a minimum of four years, with at least 50% of the deferred amount payable in equity instruments (CA-G-5, Paragraph 4.2.3).

This requirement must be disclosed in the prospectus’s Employees and Remuneration section, including a description of the deferral schedule, the vesting conditions, and the clawback triggers. The HKEX has confirmed that it will not accept a generic reference to “compliance with applicable regulatory requirements” — the prospectus must include a specific table showing the deferral percentage, the vesting period, and the equity/cash split for each category of material risk taker. This level of granularity is unprecedented in Hong Kong prospectuses and represents a significant drafting challenge for sponsors and legal counsel.

Actionable Takeaways for Issuers and Sponsors

1. Quantify employee turnover cost explicitly in the MD&A — the HKEX’s GL117-24 now expects a financial impact analysis, not just a turnover percentage, and institutional investors are discounting valuations for issuers that omit this disclosure.

2. Include a five-year sensitivity analysis of minimum wage and social insurance changes — for PRC-based issuers, a 1% change in minimum wage affects staff costs by a quantifiable amount, and the prospectus must show this sensitivity for each jurisdiction of operation.

3. Disclose the equity compensation run rate as a percentage of revenue — this is the single most important human capital cost metric for technology and biotech issuers, and it must be reconciled to the share-based payment expense under HKFRS 2.

4. Prepare a deferred compensation framework table for senior management — the SFC’s 2024 Code of Conduct amendments and the HKMA’s CA-G-5 require specific deferral percentages, vesting periods, and clawback provisions that must be disclosed in the prospectus, not deferred to the post-listing corporate governance report.

5. Include a “Pay Versus Performance” table for dual-listing applicants — while voluntary for Hong Kong-only listings, this disclosure is becoming an investor expectation and reduces the risk of regulatory inconsistency between HKEX and SEC filings.